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Troponin Puzzle
Better Conﬁrmed, and
With a Path Forward*
Allan S. Jaffe, MD
Rochester, Minnesota
There is a tendency to consider biomarkers such as the cardiac
troponins as mere diagnostic probes or prognostic markers,
rather than important elements of our armamentarium to
evaluate the pathophysiology of a variety of disease states. The
present paper from Japan by Takashio et al. (1) begins to
explore the extent to which the use of high-sensitivity cardiac
troponins may provide further pathophysiological insights,
which may lead to unique opportunities to intervene in
positive ways for patients with cardiovascular diseases, in this
instance, congestive heart failure.See page 632It has been known for years that after an acute ischemic
insult or more indolent cases, such as chronic dilated car-
diomyopathy, that heart failure often progresses in the
absence of clinically detected cardiovascular events. There-
fore, there is a degree of subclinical progression of disease,
the pathophysiology of which has not totally been eluci-
dated. There are a large number of potential reasons why
heart failure could progress in the absence of an additional
acute large insult. These could include but are not limited
to coronary endothelial dysfunction or microvascular dys-
function, concomitant comorbidities such as anemia and
diabetes, autonomic activation, systemic inﬂammation, acute
increases in pre-load causing proteolysis and release of
cardiac troponin I (cTnI) due to cell death related to apo-
ptosis via a calpain-mediated mechanism, oxidative stress,
abnormal calcium handling, and even autophagia (2). The
details related to these processes are beyond the scope of
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Radiometer.based on prior physiological studies, is that there is relative
ischemia in patients with heart failure related to poor sub-
endocardial perfusion at a time when myocardial oxygen
consumption is high. One might hypothesize that over time,
this subendocardial perfusion–demand imbalance could be
responsible for heart failure progression in the absence of
overt clinical events. This pathophysiology would also
provide at least a partial explanation for the frequent
observation of elevated cardiac troponin levels in patients
with heart failure, and its potent prognostic inﬂuence in
patients with both acute and chronic heart failure (3).
Takashio et al. (1) attack this issue of subendocardial
supply–demand imbalance directly. First, it is acknowledged
that the most important determinant of subendocardial
perfusion from the point of view of coronary blood ﬂow is
directly related to intracardiac chamber pressure. The reason
for this is that the vessels to the subendocardium tend to be
straight, making them more vulnerable to high intracavitary
pressures. At the same time, hypertrophy reduces the density
of blood vessels per gram of myocardium in the sub-
endocardial region. In addition, data suggest that there may
be abnormalities in coronary vasoreactivity in these vessels in
the setting where hypertrophy further negatively inﬂuences
subendocardial blood ﬂow. If so, this cascade has the
potential to substantially reduce subendocardial blood ﬂow
at a time when left ventricular wall stress is elevated. When
coupled with reﬂex-mediated increases in heart rate and
contractility, myocardial oxygen consumption will increase
dramatically in the face of relative hypoperfusion. This would
provide at least 1 mechanism by which heart failure could
progress in the absence of an acute event due to relative
subendocardial ischemia and its deleterious long-term effects.
The approach taken by Takashio et al. (1) is about as well
as can be done to evaluate this difﬁcult issue in humans. The
authors use high-sensitivity cardiac troponin T (hscTnT) to
evaluate this issue, measuring values across the coronary
sinus and systemically in 90 patients with dilated cardio-
myopathy and 47 control patients who had clinical indica-
tions for cardiac catheterization, but were deemed to have
reasonably normal coronary anatomy and cardiac function.
Agents that could inﬂuence coronary vasomotor tone, if
present, were discontinued 72 h before the procedure. This
is a critical control issue so that the inﬂuence of these agents
does not mask the pathophysiology, but the possibility of
an accentuated response due to the discontinuation cannot
be totally excluded. After the obligatory exclusion of some
patients due to an inability to obtain all of the requisite
information, 76 patients with heart failure and 28 controls
remained. The gradient for hscTnT release across the
coronary sinus was signiﬁcantly greater in those with heart
failure, as was the transcoronary gradient for BNP and
CRP. Intriguingly, there was a good correlation between the
transcoronary gradient and the circulating systemic level,
suggesting that peripheral blood levels were reﬂective of
myocardial release and not simply altered clearance. The
hscTnT levels were related to numerous other measured
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642parameters, but after extensive analysis, the only variable that
remained signiﬁcantly correlated with hscTnT was left
ventricular end-diastolic pressure (LVEDP). Importantly,
patients who also manifested abnormal coronary ﬂow reserve
often were in the highest quartile of hscTnT values. Thus,
such dysfunction may be additive and should be considered
when the gradient for hscTn is more markedly elevated.
This dysfunction also eventually may prove to be a target for
additional intervention.
The data appear credible. This author accepts conceptu-
ally that evaluation of the left anterior descending territory
to get a coronary atrioventricular gradient likely reﬂects an
overall pathophysiological dynamic. One could worry that
discontinuation of vasoactive medications to avoid their
confounding inﬂuences led to some degree of increase in
LVEDP that is a reﬂection of acute withdrawal, and if
so, that could introduce some confounding. However, the
continuation of these medications would also have been
viewed as confounding because it would have left direct
effects on this important parameter unopposed. In addition,
one could argue that because there are substantial data
concerning the importance of endothelial dysfunction in
patients with heart failure, and because there are data to
suggest that the prognosis of patients with endothelial
dysfunction is worse, that this entire cascade that is hypo-
thesized to be based on LVEDP could be based instead on
coronary endothelial dysfunction. In this light, the infor-
mation concerning the relative lack of abnormal vasodilator
reserve in controls is an important observation. It does
not, of course, eliminate this possibility totally, but from
the perspective of providing an important control, it does
support the concept that the LVEDP is of mechanistic
importance.
This study was done with the high-sensitivity cardiac
troponin T assay, but there is little reason to suspect that
different results might have been observed with other assays.
Assays that have still higher sensitivity are forthcoming, which
may hold further promise due to increased sensitivity and
precision (4). Most importantly, this study not only conﬁrms
an important pathophysiological principle, but it also provides
at least the hint that hscTn values may be useable to directly
monitor the downstream target of perfusion–demand
mismatch. If indeed, LVEDP is the primary contributor to the
continuing (albeit subtle) deterioration of cardiac function as
marked in this study by hscTnT, one should be able tomonitor
interventions that reduce LVEDP with these sorts of probes.
An aggressive approach to reduce central cardiac pressures was
originally advocated 25 years ago based upon the work of
Stevenson andTillisch (5), but some of the enthusiasm for this
hemodynamic-tailored approach was lost after the publication
of the ESCAPE (Evaluation Study of Congestive HeartFailure and Pulmonary Artery Catheterization Effectiveness)
trial (6). Now, with more data and potentially better probes to
provide information regarding the causes (perfusion–demand
mismatch) and consequences (cardiac myocyte death) of heart
failure progression, perhaps acute and chronic interventional
studies are againwarranted in this important area. Such studies
are becoming topical with enthusiasm for the use of more
comprehensive biomarker-guided trials (7).
This elegant research from Takashio et al. (1) begins to
express in a concrete way the exciting potential of sensitive
probes such as high-sensitivity cardiac troponin, not just to
our diagnostic armamentarium, but to the panoply of clinical
problems that might be addressed in productive ways
through proper use of cardiac biomarkers. One can conceive
long term of simple, but elegant, algorithms based on
sensitive biomarker results predicated on a pathophysiolog-
ical understanding of the progression of heart failure.
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